ArticleTranslational psychiatry2018
Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients.
Article in Translational psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Comparative Analysis of the Pre- and Post-Medication Effects of Antipsychotic Agents on the Blood-Based Oxidative Stress Biomarkers in Patients with Schizophrenia: A Meta-Analysis.Current neuropharmacology · 2023Pooled it
- Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study.Current neuropharmacology · 2022Trial
- Article
- The interplay of niacin skin flush response with plasma MDA, TNOS, iNOS and clinical symptom severity in chronic schizophrenia.BMC psychiatry · 2026Article
- Amitriptyline increases food intake via prdx-2 without altering other physiological parameters in C. elegans under a modified bacterial diet.Scientific reports · 2025Article
- Relationship between oxygen radical absorbance capacity (ORAC) index, body composition and blood biochemical markers in overweight/obese compared to normal weight subjects: a cross-sectional study.Journal of health, population, and nutrition · 2025Article
- Obesity, cytokines and psychopathology in patients with chronic schizophrenia.Frontiers in psychiatry · 2025Article
- Ferroptosis as a potential connection between schizophrenia and metabolic dysfunction-associated steatotic liver disease - a narrative review.Postepy psychiatrii neurologii · 2024Review
- Neuroprotective effects of alpha-pinene against behavioral deficits in ketamine-induced mice model of schizophrenia: Focusing on oxidative stress status.IBRO neuroscience reports · 2024Article
- Variations to plasma HSchizophrenia (Heidelberg, Germany) · 2024Article
- Thiol-disulphide Homeostasis in Patients with Schizophrenia: The Potential Biomarkers of Oxidative Stress in Acute Exacerbation of Schizophrenia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Smoking, alcohol consumption and risk of Dupuytren's disease: a Mendelian randomization study.BMC medical genomics · 2023Article
- Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone.Schizophrenia (Heidelberg, Germany) · 2023Article
- Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study.Frontiers in pharmacology · 2023Article
- Article
- Decreased Activity of Erythrocyte Catalase and Glutathione Peroxidase in Patients with Schizophrenia.Medicina (Kaunas, Lithuania) · 2022Article
- Association between MnSOD Activity and Cognitive Impairment in Unmedicated First-Episode Schizophrenia: Regulated byAntioxidants (Basel, Switzerland) · 2022Article
- Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study.European journal of medical research · 2022Article
- Association of antioxidant deficiency and the level of products of protein and lipid peroxidation in patients with the first episode of schizophrenia.Journal of molecular neuroscience : MN · 2022Article
- Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats.Iranian journal of basic medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotic pharmacotherapy is strongly obesogenic and is associated with increased oxidative stress in patients with schizophrenia. However, whether these changes reflect psychopathology, antipsychotic efficacy, or some other factor is not known. Our study aims to investigate the degree of oxidative stress in different BMI categories and to identify clinical symptomatology that may be paired with increased oxidative stress in a schizophrenia population. To this end, we performed a cross-sectional study and recruited 89 long-term inpatients with schizophrenia and collected the following variables: plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), routine biochemical analysis, and psychopathology through the Positive and Negative Syndrome Scale (PANSS). The results indicate that the levels of the lipid peroxidation product, MDA, were significantly higher in the high BMI group than the low (normal) BMI group. As expected, high BMI was associated with an atherogenic lipid profile; however, it was also associated with fewer psychopathological symptoms. Multiple regression analysis found that MDA levels, the PANSS general psychopathology subscore, and triglyceride levels (all p < 0.05) were independent contributors to the BMI in patients. These results suggested that oxidative stress may play an important role in antipsychotic-induced weight gain. Further investigations using the longitudinal design in first-episode schizophrenia patients are needed to explore the beneficial effect of antioxidants on the abnormal lipid metabolism mediated by antipsychotic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.